Published in Medical Letter on the CDC and FDA, February 18th, 2007
The federally funded comparative effectiveness review of these drugs - called atypical antipsychotics - identified the medications' potential for serious side effects while pointing to an "urgent need" for more research into new treatments for the growing population of dementia patients who display severe agitation.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA